[go: up one dir, main page]

MX2016002273A - Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib. - Google Patents

Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib.

Info

Publication number
MX2016002273A
MX2016002273A MX2016002273A MX2016002273A MX2016002273A MX 2016002273 A MX2016002273 A MX 2016002273A MX 2016002273 A MX2016002273 A MX 2016002273A MX 2016002273 A MX2016002273 A MX 2016002273A MX 2016002273 A MX2016002273 A MX 2016002273A
Authority
MX
Mexico
Prior art keywords
antagonist
dinaciclib
combination
treating cancer
combination therapies
Prior art date
Application number
MX2016002273A
Other languages
English (en)
Other versions
MX376078B (es
Inventor
Joseph H Phillips
Peter Richard Strack
Robert Booher
Venkataraman Sriram
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2016002273A publication Critical patent/MX2016002273A/es
Publication of MX376078B publication Critical patent/MX376078B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente revelación describe las terapias de combinación que comprenden un antagonista del receptor de Muerte Programada 1 (PD-1) y el inhibidor de CDK dincaciclib, y el uso de las terapias de combinación para el tratamiento del cáncer, y en particular para el tratamiento de cánceres que expresan la PD-L1.
MX2016002273A 2013-08-20 2014-08-15 Combinación de un antagonista de pd -1 y dinaciclib para usarse en el tratamiento de cáncer. MX376078B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361867760P 2013-08-20 2013-08-20
PCT/US2014/051171 WO2015026634A1 (en) 2013-08-20 2014-08-15 Treating cancer with a combination of a pd-1 antagonist and dinaciclib

Publications (2)

Publication Number Publication Date
MX2016002273A true MX2016002273A (es) 2016-05-31
MX376078B MX376078B (es) 2025-03-07

Family

ID=52484060

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002273A MX376078B (es) 2013-08-20 2014-08-15 Combinación de un antagonista de pd -1 y dinaciclib para usarse en el tratamiento de cáncer.

Country Status (11)

Country Link
US (1) US9827309B2 (es)
EP (1) EP3035964B1 (es)
JP (1) JP6586087B2 (es)
KR (1) KR102232153B1 (es)
CN (1) CN105451770B (es)
AU (1) AU2014309199B2 (es)
CA (1) CA2920113A1 (es)
ES (1) ES2827679T3 (es)
MX (1) MX376078B (es)
RU (1) RU2705795C2 (es)
WO (1) WO2015026634A1 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2170959E (pt) * 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
EP2928474B1 (en) 2012-12-07 2018-11-14 ChemoCentryx, Inc. Diazole lactams
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
RS59853B1 (sr) 2014-03-14 2020-02-28 Novartis Ag Molekuli anti-lag-3 antitela i njihove upotrebe
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
WO2016075095A2 (en) * 2014-11-10 2016-05-19 Ventana Medical Systems, Inc. Using contextual information to classify nuclei in histology images
CA2976072A1 (en) 2015-02-09 2016-08-18 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors and pd-1 inhibitors for treating cancer
US10948492B2 (en) 2015-03-06 2021-03-16 Dana-Farber Cancer Institute, Inc. PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
PT3297438T (pt) 2015-05-21 2022-01-25 Chemocentryx Inc Moduladores de ccr2
CA2986114A1 (en) * 2015-05-22 2016-12-01 La Trobe University Method of diagnosis of breast cancer
MX390878B (es) * 2015-06-16 2025-03-21 Merck Patent Gmbh Usos medicos de antagonista de ligando 1 de muerte programada (pd-l1).
HK1250033A1 (zh) 2015-07-13 2018-11-23 Cytomx Therapeutics Inc. 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法
US11001628B2 (en) * 2015-07-29 2021-05-11 Novartis Ag Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer
HK1251475A1 (zh) * 2015-10-08 2019-02-01 Macrogenics, Inc. 用於癌症治疗的联合疗法
BR112018011781A2 (en) 2015-12-14 2018-12-04 Macrogenics, Inc. bispecific molecule having one or more epitope binding sites capable of immunospecific binding to (one) pd-1 epitope (s) and one or more epitope binding sites capable of immunospecific binding to (one) epitope (s) -4, and pharmaceutical composition
JP7126941B2 (ja) 2015-12-22 2022-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ
US11865116B2 (en) 2016-03-24 2024-01-09 Cothera Bioscience, Inc. Treatment of cancer with TG02
CN109310677A (zh) 2016-04-07 2019-02-05 凯莫森特里克斯股份有限公司 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷
CN109310685B (zh) 2016-04-12 2021-10-29 伊莱利利公司 用于治疗癌症的notch和pi3k/mtor抑制剂的组合疗法
KR102418765B1 (ko) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법
TWI755395B (zh) 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
CN109475629A (zh) 2016-05-20 2019-03-15 伊莱利利公司 用notch和pd-1或pd-l1抑制剂的组合治疗
EP3463453A1 (en) * 2016-05-23 2019-04-10 Eli Lilly and Company Combination of pembrolizumab and abemaciclib for the treatment of cancer
WO2017205213A1 (en) * 2016-05-23 2017-11-30 Eli Lilly And Company Combination therapy of abemaciclib and immune checkpoint modulators for use in the treatment of cancer
US11124571B2 (en) * 2016-05-25 2021-09-21 Case Western Reserve University Methods of sensitizing cancer to immunotherapy
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
CA3036384A1 (en) 2016-09-14 2018-03-22 Gilead Sciences, Inc. Syk inhibitors
EP3515940A1 (en) * 2016-09-26 2019-07-31 ImClone LLC Combination therapy for cancer
JP7424727B2 (ja) 2016-09-29 2024-01-30 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッド ヘテロダイマー免疫グロブリン構造体及びその製造方法
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
AU2017353427A1 (en) 2016-11-02 2019-05-16 Bristol-Myers Squibb Company Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
EA201990894A9 (ru) * 2016-11-18 2019-11-27 Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
WO2018157863A1 (en) * 2017-03-03 2018-09-07 Peking University Method and compound for modifying circadian clock
WO2018183408A1 (en) * 2017-03-31 2018-10-04 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
CN110799537B (zh) * 2017-06-25 2023-07-28 西雅图免疫公司 抗pd-1抗体及其制备和使用方法
CN111712242B (zh) 2017-09-25 2023-11-24 凯莫森特里克斯股份有限公司 使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗
WO2019087087A1 (en) 2017-11-03 2019-05-09 Aurigene Discovery Technologies Limited Dual inhibitors of tim-3 and pd-1 pathways
US12193994B2 (en) 2017-11-06 2025-01-14 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
EA202090749A1 (ru) 2017-11-06 2020-08-19 Ориджен Дискавери Текнолоджис Лимитед Способы совместной терапии для иммуномодуляции
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
AU2019205784B2 (en) 2018-01-08 2024-07-25 Chemocentryx, Inc. Methods of treating solid tumors with CCR2 antagonists
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
CN110215516A (zh) * 2018-03-02 2019-09-10 南京大学 一种抑制cdk5协同免疫治疗在抑制乳腺癌中的应用
US20210379024A1 (en) 2018-03-14 2021-12-09 Aurigene Discovery Technologies Limited Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds
US11555071B2 (en) 2018-06-03 2023-01-17 Lamkap Bio Beta Ltd. Bispecific antibodies against CEACAM5 and CD47
EP3806846A1 (en) 2018-06-15 2021-04-21 Board of Regents, The University of Texas System Methods of treating and preventing breast cancer with s-equol
US20190380998A1 (en) 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
SG11202100208VA (en) * 2018-07-09 2021-02-25 Precigen Inc Fusion constructs and methods of using thereof
CN110613850A (zh) * 2019-05-24 2019-12-27 中国医学科学院北京协和医院 周期蛋白依赖性激酶1抑制剂及其用途
WO2021053587A1 (en) 2019-09-18 2021-03-25 Klaus Strein Bispecific antibodies against ceacam5 and cd3
WO2021092059A1 (en) * 2019-11-04 2021-05-14 Northwestern University Cytotoxic lipid particles for treating glioblastoma
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
US20230355757A1 (en) * 2019-12-20 2023-11-09 Formycon Ag Formulations of anti-pd1 antibodies
JPWO2022004760A1 (es) 2020-06-30 2022-01-06
KR20230069965A (ko) * 2020-09-17 2023-05-19 머크 샤프 앤드 돔 엘엘씨 암을 치료하기 위한 항-ilt4 항체 또는 그의 항-pd-1 항체와의 조합물의 투여 요법
AU2021400227A1 (en) 2020-12-18 2023-04-27 Lamkap Bio Beta Ltd Bispecific antibodies against ceacam5 and cd47
JP2025523424A (ja) 2022-06-16 2025-07-23 ランカプ バイオ ベータ リミテッド Ｃｅａｃａｍ５およびｃｄ４７に対する二重特異性抗体ならびにｃｅａｃａｍ５およびｃｄ３に対する二重特異性抗体の併用療法
WO2025042742A1 (en) 2023-08-18 2025-02-27 Bristol-Myers Squibb Company Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
WO2025110822A1 (ko) * 2023-11-24 2025-05-30 주식회사 메드팩토 피브로넥틴 엑스트라도메인 b (extradomain b of fibronectin, edb-fn) 및 전환성장인자 베타(transforming growth factor β, tgfβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도
CN120459303A (zh) * 2025-05-29 2025-08-12 贵州医科大学 包含cdk2抑制剂和抗pd-1抗体的组合物在制备抗肿瘤药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CN1214043C (zh) 1998-12-01 2005-08-10 蛋白质设计实验室股份有限公司 抗γ－干扰素的人化抗体
US7115261B1 (en) * 1999-02-12 2006-10-03 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
HRP20151102T1 (xx) 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
US20100055111A1 (en) * 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
PT2170959E (pt) * 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
CA2699761A1 (en) 2007-09-17 2009-03-26 Schering Corporation Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
US20100286038A1 (en) * 2007-09-21 2010-11-11 Valentyn Antochshuk Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
EA201170375A1 (ru) 2008-08-25 2012-03-30 Эмплиммьюн, Инк. Антагонисты pd-1 и способы их применения
SMT202500126T1 (it) 2008-12-09 2025-05-12 Hoffmann La Roche Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
SI2691112T1 (en) 2011-03-31 2018-07-31 Merck Sharp & Dohme Corp. STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH
BR112014002353B1 (pt) * 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
CA2895284A1 (en) * 2013-02-07 2014-08-14 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer

Also Published As

Publication number Publication date
EP3035964B1 (en) 2020-09-23
KR102232153B1 (ko) 2021-03-24
JP2016528286A (ja) 2016-09-15
AU2014309199B2 (en) 2018-04-19
EP3035964A4 (en) 2017-03-15
WO2015026634A1 (en) 2015-02-26
CN105451770B (zh) 2020-02-07
RU2016109811A (ru) 2017-09-22
MX376078B (es) 2025-03-07
US20160193334A1 (en) 2016-07-07
CN105451770A (zh) 2016-03-30
AU2014309199A1 (en) 2016-02-18
CA2920113A1 (en) 2015-02-26
ES2827679T3 (es) 2021-05-24
EP3035964A1 (en) 2016-06-29
JP6586087B2 (ja) 2019-10-02
KR20160044480A (ko) 2016-04-25
RU2705795C2 (ru) 2019-11-12
RU2016109811A3 (es) 2018-06-19
US9827309B2 (en) 2017-11-28

Similar Documents

Publication Publication Date Title
MX2016002273A (es) Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib.
SG10201806656UA (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
PH12016501550A1 (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
TW201613635A (en) Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
MX2017015308A (es) Combinacion de un antagonista de pd-1 y un oligonucleotido tipo cpg-c para tratar cancer.
ZA201806633B (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
MY193229A (en) Pd-l1 antagonist combination treatments
MA40344A (fr) Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer
MX2017005553A (es) Terapia de combinacion para cancer.
MX2022001757A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer.
PH12015502091A1 (en) Cdc7 inhibitors
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
MX393818B (es) Terapias de combinación para el tratamiento de cáncer.
NZ731467A (en) Anti-tim3 antibodies and methods of use
JO3553B1 (ar) تعديل المناعة ضد الورم
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
MX2017002364A (es) Terapia de combinacion para tratamiento de cancer.
MX2016016667A (es) Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer.
HK40004572A (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors

Legal Events

Date Code Title Description
FG Grant or registration